Search | Clinical Trials Finder

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 52
States / cities: Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 35
States / cities: Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Allo-hMSCs, Placebo; Drug
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 30 Days
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Alopecia Areata
Interventions: Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Male Pattern Hair Loss
Interventions: HST 001, Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Scleroderma, Systemic
Interventions: GSK2330811, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GM604, Placebo comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions: Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Canakinumab, Metformin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more

Conditions: Herpes Zoster, HIV Infections
Interventions: ZOSTAVAX, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 43
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Melanoma
Interventions: Talimogene Laherparepvec, Pembrolizumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more

Conditions: Preterm Birth, Pregnancy, Multifetal
Interventions: 17 alpha-hydroxyprogesterone caproate (17P); Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 795 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 14
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more

Conditions: Dengue
Interventions: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 20 Years to 49 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol, Placebo, Methotrexate; Biological · Other
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: AZD4076, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Conditions: HIV Infections
Interventions: ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more

Conditions: Embolism, Thrombosis
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Lymphoma,Non-Hodgkin
Interventions: Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 16
States / cities: West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more

Conditions: SARS CoV 2 Infection, Pneumonia
Interventions: SP16 (6mg), Placebo, SP16 (12 mg); Drug · Other
Lead sponsor: Serpin Pharma, LLC; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions: Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Placebo, GLSI-100; Biological
Lead sponsor: Greenwich LifeSciences, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 51
States / cities: Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more

Search by objective public record fields.

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Anticholinergic vs. Botox Comparison Study

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Intralesional Steroids in the Treatment of Alopecia Areata

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

SP16 as a Therapeutic for COVID-19 Induced ARDS

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects